carboxyamido-triazole has been researched along with Adenocarcinoma Of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hollis, D; Mahoney, J; Ratain, MJ; Rini, B; Rosner, G; Small, E; Stadler, WM; Zaentz, SD | 1 |
| Dutcher, JP; Friedland, DM; Leon, L; Manola, J; Roth, B; Wilding, G | 1 |
2 trial(s) available for carboxyamido-triazole and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Research Design; Survival Rate; Treatment Outcome; Triazoles | 2005 |
Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Patient Selection; Time Factors; Treatment Outcome; Triazoles | 2005 |